Quantcast
Last updated on April 16, 2014 at 17:33 EDT

Latest Vanda Pharmaceuticals Inc. Stories

2013-06-28 20:22:31

WAYNE, Pa., June 28, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/vnda) announces that a class action lawsuit has been filed in the United States District Court for the District of Columbia on behalf of purchasers of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NASDAQ: VNDA) between December 18, 2012 and June 18, 2013, inclusive (the "Class Period"). (Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO ) For more information regarding...

2013-06-25 16:26:37

NEW YORK, June 25, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies....

2013-06-19 16:25:56

NEW YORK, June 19, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NASDAQ: VNDA)(CUSIP: 921659108) who purchased Vanda common stock between May 8, 2012 and June 18, 2013 (the "Class Period"). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The investigation concerns whether Vanda and...

2013-06-17 20:21:16

Data presented at ENDO 2013, the Endocrine Society's 95th Annual Meeting WASHINGTON, June 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95(th) Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. This effect further confirms tasimelteon's potential to reset the master body clock and address the circadian desynchrony which is...

2013-06-06 08:29:47

NEW YORK, June 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Clovis Oncology Inc. (NASDAQ: CLVS), MannKind Corporation (NASDAQ: MNKD), TESARO Inc. (NASDAQ: TSRO), Peregrine Pharmaceuticals (NASDAQ: PPHM), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports free of charge - including full price targets, industry...

2013-06-05 20:24:00

Data presented as a late breaking abstract at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies WASHINGTON, June 5, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and...

2013-05-31 16:24:00

Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON, May 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2013 at 2:30 p.m. Eastern Time. The...

2013-05-31 08:24:00

WASHINGTON, May 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tasimelteon, a circadian regulator. Vanda is seeking FDA approval of tasimelteon for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. Tasimelteon was developed to address a significant unmet medical need, the treatment of Non-24, for which there are currently no FDA...

2013-05-30 20:21:28

-- Data to be presented at SLEEP 2013 27th Annual Meeting of the Associated Professional Sleep Societies and the Endocrine Society's 95th Annual Meeting WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the Phase III studies of tasimelteon in Non-24-Hour Disorder (Non-24) will be presented at SLEEP 2013, the 27th Annual Meeting of the Associated Professional Sleep Societies, LLC being held from June 1, 2013...

2013-05-24 00:20:29

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM). Vanda was honored at the TCM's 25(th) Annual Tech Awards Celebration held in Bethesda, Maryland. The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in Maryland and the surrounding regions. "We are deeply honored to...